Patents by Inventor Alan Jonason

Alan Jonason has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of semaphorin-4D binding molecules for treating neurodegenerative disorders
    Patent number: 10800853
    Abstract: Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: October 13, 2020
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Maurice Zauderer, William J. Bowers, Alan Jonason
  • USE OF SEMAPHORIN-4D BINDING MOLECULES FOR TREATING NEURODEGENERATIVE DISORDERS
    Publication number: 20190322757
    Abstract: Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.
    Type: Application
    Filed: July 2, 2019
    Publication date: October 24, 2019
    Inventors: Ernest S. Smith, Maurice Zauderer, William J. Bowers, Alan Jonason
  • Use of semaphorin-4D binding molecules for treating neurodegenerative disorders
    Patent number: 10385136
    Abstract: Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: August 20, 2019
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Maurice Zauderer, William J. Bowers, Alan Jonason
  • USE OF SEMAPHORIN-4D BINDING MOLECULES FOR TREATING NEURODEGENERATIVE DISORDERS
    Publication number: 20170198053
    Abstract: Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.
    Type: Application
    Filed: March 21, 2017
    Publication date: July 13, 2017
    Inventors: Ernest S. Smith, Maurice Zauderer, William J. Bowers, Alan Jonason
  • Use of semaphorin-4D binding molecules for treating neurodegenerative disorders
    Patent number: 9598495
    Abstract: Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: March 21, 2017
    Assignee: VACCINEX, INC.
    Inventors: Ernest S. Smith, Maurice Zauderer, William J. Bowers, Alan Jonason
  • Use of semaphorin-4D binding molecules for treating neurodegenerative disorders
    Patent number: 9249227
    Abstract: Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: February 2, 2016
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Maurice Zauderer, William J. Bowers, Alan Jonason
  • USE OF SEMAPHORIN-4D BINDING MOLECULES FOR TREATING NEURODEGENERATIVE DISORDERS
    Publication number: 20150353641
    Abstract: Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.
    Type: Application
    Filed: June 29, 2015
    Publication date: December 10, 2015
    Applicant: VACCINEX, INC.
    Inventors: Ernest S. Smith, Maurice Zauderer, William J. Bowers, Alan Jonason
  • Use of Semaphorin-4D Binding Molecules for Treating Neurodegenerative Disorders
    Publication number: 20150110800
    Abstract: Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 23, 2015
    Inventors: Ernest S. Smith, Maurice Zauderer, William J. Bowers, Alan Jonason